From 1 October 2015, the PBS listing for Eylea® includes the treatment of macula oedema from either diabetic retinopathy or central retinal vein occlusion.
Read MoreFrom 1 October 2015, the PBS listing for Eylea® includes the treatment of macula oedema from either diabetic retinopathy or central retinal vein occlusion.
Read MoreMDFA says the addition of ranibizumab (Lucentis) to the Pharmaceutical Benefits Scheme provides patients with affordable access to treatment for diabetic macular oedema and retinal vein occlusion.
Read MoreWe’ve audited the six largest health funds to find out the benefits they offer for low vision aids and technology.
Read MoreAfter extensive lobbying by MDFA, SA Health has confirmed funding for an additional seven eye clinics per month.
Read MoreMDFA has been advocating for our community on the issue of PIN-only authorisation credit cards.
Read MoreMDFA has welcomed new treatment options for diabetic macular oedema and retinal vein occlusion.
Read MoreAn article outlining MDFA’s ‘Ripple Effect of Vision Loss’ research has been published in peer reviewed journal, ‘Aging and Mental Health’.
Read MoreThe Foundation has been strongly advocating against age discrimination in the NDIS.
Read MoreMDFA is calling on the Federal Government to rethink how older Australians will be cared for given the NDIS excludes people who acquire a disability at the age of 65 and over.
Read More